{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:02:55Z","timestamp":1781521375110,"version":"3.54.1"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead"},{"name":"NIH","award":["R24 AI106039"],"award-info":[{"award-number":["R24 AI106039"]}]},{"name":"NIH","award":["R01 MH124590"],"award-info":[{"award-number":["R01 MH124590"]}]},{"name":"University of California San Diego Center for AIDS Research","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Machine learning (ML) algorithms may be effective at improving the HCV care cascade. One ML algorithm, developed using U.S. ambulatory electronic medical records (EMR), demonstrated the ability to identify people infected with HCV earlier than conventional testing strategies among those with indications for screening. We evaluated the potential cost-effectiveness of ML-enabled screening for the early identification of undiagnosed HCV among people in care in the U.S. An HCV natural history Markov model was developed to evaluate the cost-effectiveness of the ML algorithm-enabled screening compared to conventional testing over the training data period. Based on the training data, the ML algorithm identified patients on average 6.5 months earlier than conventional testing strategies. We compared the status quo to intervention scenarios using the ML algorithm at different recall levels (proportion of HCV patients identified, 5\u2013100%). We identified the optimal algorithm recall level, which maximized health (measured in quality-adjusted life years, QALYs) while staying under a willingness-to-pay threshold of USD$100,000\/QALY gained. ML-enabled screening was cost-effective (ICER &lt; $100 k\/QALY gained) in identifying undiagnosed HCV patients for recall levels up to 30%. The optimal recall level was 30% (Precision 0.27%), which resulted in a mean ICER of $94,022\/QALY gained. ML-enabled screening for the early identification of undiagnosed HCV patients could be cost-effective in the U.S. Prospective evaluation of real-world effectiveness is warranted.<\/jats:p>","DOI":"10.3390\/v18030299","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:55:01Z","timestamp":1772463301000},"page":"299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-2348","authenticated-orcid":false,"given":"Thomas C. S.","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pitcher","sequence":"additional","affiliation":[{"name":"IQVIA, Copenhagen 2200, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frankeberger","sequence":"additional","affiliation":[{"name":"Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-9737","authenticated-orcid":false,"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.idc.2018.02.008","article-title":"Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling","volume":"32","author":"Chhatwal","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 323, 970\u2013975.","DOI":"10.1001\/jama.2020.1123"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yehia, B.R., Schranz, A.J., Umscheid, C.A., and Lo Re, V. (2014). The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101554"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amepre.2021.03.011","article-title":"Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic","volume":"61","author":"Kaufman","year":"2021","journal-title":"Am. J. Prev. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.14283\/jpad.2019.10","article-title":"Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer\u2019s Disease Patients in the General Population","volume":"6","author":"Alamuri","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/big.2015.0020","article-title":"Population-Level Prediction of Type 2 Diabetes from Claims Data and Analysis of Risk Factors","volume":"3","author":"Razavian","year":"2015","journal-title":"Big Data"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10521","DOI":"10.1038\/s41598-020-67013-6","article-title":"Finding undiagnosed patients with hepatitis C infection: An application of artificial intelligence to patient claims data","volume":"10","author":"Doyle","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e100651","DOI":"10.1136\/bmjhci-2022-100651","article-title":"Finding undiagnosed patients with hepatitis C virus: An application of machine learning to US ambulatory electronic medical records","volume":"30","author":"Rigg","year":"2023","journal-title":"BMJ Health Care Inform."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population","volume":"290","author":"Salomon","year":"2003","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwf100","article-title":"Empirically Calibrated Model of Hepatitis C Virus Infection in the United States","volume":"156","author":"Salomon","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep4.1457","article-title":"Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013\u20132016","volume":"4","author":"Bradley","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: A long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciy098","article-title":"Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States","volume":"67","author":"Barocas","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12659\/AOT.892530","article-title":"Donor hepatitis C sero-status does not impact survival in liver transplantation","volume":"20","author":"Montenovo","year":"2015","journal-title":"Ann. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.jval.2021.04.979","article-title":"PPM7 Finding Undiagnosed Patients with Hepatitis C Virus: An Application of Artificial Intelligence to US Ambulatory Electronic Medical Records","volume":"24","author":"Rigg","year":"2021","journal-title":"Value Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"ref_30","first-page":"531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: A managed care perspective","volume":"17","author":"McGarry","year":"2011","journal-title":"J. Manag. Care Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","article-title":"Economic burden of hepatitis C-associated diseases in the United States","volume":"19","author":"Klimack","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/cid\/ciz063","article-title":"Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States","volume":"69","author":"Chaillon","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","unstructured":"(2026, February 17). Gilead Subsidiary to Launch Authorized Generics of Epclusa\u00ae (Sofosbuvir\/Velpatasvir) and Harvoni\u00ae (Ledipasvir\/Sofosbuvir) for the Treatment of Chronic Hepatitis C: Business Wire. Available online: https:\/\/www.gilead.com\/news\/news-details\/2018\/gilead-subsidiary-to-launch-authorized-generics-of-epclusa-sofosbuvirvelpatasvir-and-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronic-hepatitis-c."},{"key":"ref_34","unstructured":"Veterans Affairs (2026, February 17). Federal Supply Schedule, Available online: https:\/\/wwwfss.va.gov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores","volume":"100","author":"Thein","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol. Assess."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e3355","DOI":"10.1093\/cid\/ciaa362","article-title":"Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States","volume":"73","author":"Chaillon","year":"2021","journal-title":"Clin Infect Dis."},{"key":"ref_39","unstructured":"(2026, February 17). Life-Tables by Country 2020: World Health Organization. Available online: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/healthy-life-expectancy-(hale)."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jvh.13278","article-title":"Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation","volume":"27","author":"Higashi","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s10115-023-01851-4","article-title":"Hepatitis C Virus prediction based on machine learning framework: A real-world case study in Egypt","volume":"65","author":"Shams","year":"2023","journal-title":"Knowl. Inf. Syst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1038\/s41598-023-36605-3","article-title":"Hybrid model for precise hepatitis-C classification using improved random forest and SVM method","volume":"13","author":"Lilhore","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:06:36Z","timestamp":1773219996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["v18030299"],"URL":"https:\/\/doi.org\/10.3390\/v18030299","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}